Clinical Trial on the Preventive Effect of Intravaginal Prasterone on Recurrent Urinary Tract Infections in Postmenopausal Women

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

May 31, 2020

Primary Completion Date

February 28, 2021

Study Completion Date

February 28, 2021

Conditions
Recurrent Urinary Tract InfectionPostmenopausePostmenopausal SyndromePostmenopausal SymptomsMenopause
Interventions
DRUG

Prasterone

Nightly intravaginal prasterone insert (6.5 mg prasterone at a concentration of 0.50%) for 24 weeks.

DRUG

Placebo

Nightly intravaginal placebo insert (Witepsol H-15, a mix of synthetic triglycerides) for 24 weeks.

Trial Locations (1)

40205

University of Louisville Urogynecology at Springs Medical Center, Louisville

Sponsors
All Listed Sponsors
collaborator

AMAG Pharmaceuticals, Inc.

INDUSTRY

lead

Olivia Cardenas-Trowers, M.D.

OTHER